NCI-H358

NCI-H358/NCI-H358细胞系/NCI-H358细胞株/NCI-H358人非小细胞肺癌细胞

Cell line name NCI-H358

Synonyms H358; H-358; NCIH358

Accession CVCL_1559

Resource Identification Initiative To cite this cell line use: NCI-H358 (RRID:CVCL_1559)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Population: Caucasian.

Doubling time: 38 hours (Note=In RPMI 1640 + 10% FBS), 76 hours (Note=In ACL-3), 60 hours (Note=In ACL-3 + BSA) (PubMed=3940644); 38 hours (PubMed=29681454); 38 hours (ECACC=95111733).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Proteome analysis by 2D-DE/MS.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Caution: NCI-H358 and NCI-H358M (Cellosaurus=CVCL_JA53) could be identical.

Misspelling: H1358; PubMed=1311061; Note=In table 1.

Derived from site: In situ; Lung; UBERON=UBERON_0002048.

Cell type: Club cell; CL=CL_0000158.

PubMed=1311061

Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D., Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Oncogene 7:171-180(1992)

 

PubMed=1565469

Bodner S.M., Minna J.D., Jensen S.M., D'Amico D., Carbone D.P., Mitsudomi T., Fedorko J., Buchhagen D.L., Nau M.M., Gazdar A.F., Linnoila R.I.

Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

Oncogene 7:743-749(1992)

 

PubMed=7972006; DOI=10.1073/pnas.91.23.11045; PMCID=PMC45163

Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.

Mutations and altered expression of p16INK4 in human cancer.

Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

 

PubMed=8806092; DOI=10.1002/jcb.240630505

Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

NCI-Navy Medical Oncology Branch cell line data base.

J. Cell. Biochem. Suppl. 24:32-91(1996)

 

PubMed=8806101; DOI=10.1002/jcb.240630514

Lokshin A.E., Levitt M.L.

Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.

J. Cell. Biochem. Suppl. 24:186-197(1996)

 

PubMed=9649128; DOI=10.1038/bjc.1998.361; PMCID=PMC2150402

Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.

Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.

Br. J. Cancer 77:2162-2170(1998)

 

PubMed=11030152; DOI=10.1038/sj.onc.1203815

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Oncogene 19:4632-4639(2000)

 

PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0

Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.

Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.

Cancer Genet. Cytogenet. 125:87-99(2001)